No Data
Akero a New Buy at Citi on Liver Disease Asset
Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup
Promising Potential of Akero Therapeutics' Efruxifermin Highlighted by Positive Phase 2b HARMONY Study Results
Akero Therapeutics (AKRO) Receives a Buy From Phillip Securities
Promising Clinical Trial Results and Future Potential Justify Buy Rating for Akero Therapeutics
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting 2024
No Data
No Data